BioMimetic FDA submissions complete
Posted on February 18, 2010 at 7:21 amBioMimetic Therapeutics’ Augment Bone Graft product is another step closer to U.S. commercialization. The company (Ticker: BMTI) said Wednesday it sent the third and final portion of its premarket approval application to the FDA.
permalink | Comment on this post
First 5% institutional investor for Cumberland
Posted on February 1, 2010 at 8:06 am
JPMorgan Chase late last week declared it has amassed a 1.7 million-share stake in Cumberland Pharmaceuticals, which went public last August and now sports a market cap (Ticker: CPIX) of about $240 million. The New York-based bank’s disclosure appears to make it the second-largest investor in Cumberland, trailing only CEO A.J. Kazimi.
permalink | Comment on this post
Cumberland Pharmaceuticals signs South Korea deal
Posted on December 9, 2009 at 11:20 amCumberland Pharmaceuticals said today it has reached an agreement with Korean-based pharmaceutical company DB Pharm Korea to commercialize its ibuprofen drug Caldolor in South Korea. Go here to read about a similar deal for the drug in Australia and New Zealand and here for more recent news from the company. Cumberland’s stock (Ticker: CPIX) was trading up about 2 percent on the news.
permalink | Comment on this post
Positive results from Caldolor study
Posted on November 23, 2009 at 11:42 amCumberland Pharmaceuticals (Ticker: CPIX) today said it got positive results in a study evaluating the safety and effectiveness of its injectable ibuprofen drug Caldolor for reducing fever in hospitalized burn patients during the first 24 hours of treatment. Other news related to the recently approved drug is available here.
permalink | Comment on this post
Cumberland takes Caldolor Down Under
Posted on October 29, 2009 at 1:43 pm
Four months after receiving approval to sell its injectable ibuprofen in the United States, Cumberland Pharmaceuticals has signed a licensing deal to market the product in Australia and New Zealand. The Nashville company will step back and let Phebra handle the regulatory and marketing work there while receiving a cut in sales.
permalink | Comment on this post
Caldolor does the trick
Posted on October 19, 2009 at 2:32 pm
Cumberland Pharmaceuticals said today that the results of a Phase III study of Caldolor, its intravenous ibuprofen, show patients getting 800 mg of the drug every six hours after orthopedic and abdominal surgery need fewer narcotics and have less pain than those receiving only morphine. The company’s stock (Ticker: CPIX) is headed into the close up nearly 5 percent on the news.
permalink | Comment on this post
All together now: Buy Cumberland Pharmaceuticals
Posted on September 22, 2009 at 9:19 amIn contrast to the cacophony over Emdeon, the analyst community is all kumbaya over the prospects of Cumberland Pharmaceuticals, which also went public a month ago. Morgan Joseph, Jefferies and UBS all initiated coverage of the stock yesterday with ‘buy’ ratings. The first two firms also have $21 price targets for the stock (Ticker: CPIX), which trades this morning around $17.
permalink | Comment on this post
Cumberland’s Caldolor ahead of schedule
Posted on September 9, 2009 at 9:41 amNewly public Cumberland Pharmaceuticals says its injectable painkiller Caldolor, which received FDA approval in June, is ready to go earlier than previously planned. Shares of Cumberland (Ticker: CPIX) are down about 0.8 percent this morning.
permalink | Comment on this post
Nashville’s newest public company down a bit
Posted on August 11, 2009 at 12:15 pm
More than 1.4 million shares of Cumberland Pharmaceuticals (Ticker: CPIX) changed hands during the first two hours of its public life. By lunch time, the shares were off about 1 percent, giving Nashville-based Cumberland a market cap of roughly $285 million.
permalink | Comment on this post
Local pharma firm’s IPO ‘couldn’t come at a worse time’
Posted on August 10, 2009 at 12:30 pm
Brian Laegeler at Morningstar says Cumberland Pharmaceuticals’ chances of successfully carrying out its post-IPO acquisition plans are slim. The Nashville-based company is expected to raise $100 million this week, but Laegeler sees higher costs ahead.
In our view, there couldn’t be a worse time for a small drug company to launch an acquisition program. Most big and specialty pharma companies we cover are desperate to rebuild sparse pipelines and have access to piles of cash. It’s highly unlikely that Cumberland, with its limited resources, will attract a sizable or promising opportunity for a reasonable price.
permalink | Comment on this post
FDA OKs Cumberland’s IV ibuprofen
Posted on June 12, 2009 at 6:50 am
Federal drug regulators have approved Cumberland Pharmaceuticals’ Caldolor, an intravenous version of ibuprofen that becomes the company’s third portfolio drug. In their quarterly report with the SEC last month, Cumberland officials called Caldolor their “most significant product opportunity” and cited stats that put the U.S. market for injectable pain relievers at more than $300 million per year.
permalink | Comment on this post
Former Senator to advise stem cell venture
Posted on February 12, 2009 at 9:16 amJim Sasser has been named to the advisory board of Maryland-based Neuralstem, which is developing brain and spinal cord stem cells to treat various diseases. Sasser, a former U.S. ambassador to China, will focus on that country.
permalink | Comment on this post
BioMimetic CEO sells block of stock to biggest investor
Posted on January 30, 2009 at 7:12 amSam Lynch unloads 50,000 shares in part to cover taxes from exercising options last year. As it has been many times over the past few years, Denmark-based Novo A/S was a willing buyer.
permalink | Comment on this post
Nashville I-bank to assist Canadian firm
Posted on January 26, 2009 at 11:22 pmThe team of health care specialists at Velocity Health have been hired to assist publicly traded drug developer Orbus in reviewing strategic alternatives.
permalink | Comment on this post
Cumberland taps new product director
Posted on January 13, 2009 at 6:17 pmFrom Red Orbit:
Cumberland Pharmaceuticals Inc. is pleased to announce the appointment of Barry Lee as Product Director. In this role, Mr. Lee will draw upon his 24 years of pharmaceutical sales and marketing experience to lead the prospective launch and commercialization of new products for the company.
Recent Comments
Idiot, anybody that would invest in this guy’s ideas...
This is for Gretchen Wilson, I am so proud of you going out on your own,...
Did SItel have any dividend payments in 2009 or 2010?
I’d say planting your flag in the ground so...
Calling a bottom after the fact is not what I call nailing the bottom!
My boyfriend and I live just a few blocks away from Omega.I...
does kroger use this “window” to decide how many illegal aliens they...
Are the pens and pad of paper on the night stand taxed?...
This is hilarious. This story comes up...
Congratulations, Anaheim…you just made a deal with the...
hmmm…how are they going to make that up when they layed off 22 people...
It is not hard to look good when you are comparing year over year to...